(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | -24MM | -203% |
Operating Income | 50.5MM | -2713% |
Operating Expenses | 23MM | -16% |
Net Income | - | - |
R&D | 16.6MM | +1% |
G&A | 6.4MM | +13% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
It's been a good week for Spero Therapeutics, Inc. ( NASDAQ:SPRO ) shareholders, because the company has just released...
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript March 13, 2024 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $0.96, expectations were $-0.1. SPRO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to the […]
Most readers would already be aware that Spero Therapeutics' (NASDAQ:SPRO) stock increased significantly by 35% over...
Q4 2023 Spero Therapeutics Inc Earnings Call
Spero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 633.33% and 278.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024Initiated enrollment in PIVOT-PO, a pivotal Phase 3 clinical trial of oral Tebipenem HBr in cUTI Submitted IND for SPR206 and received FDA clearance to proceed with Phase 2 clinical trialReiterate expected cash runway into late 2025Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Sp
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will host a conference call and live audio webcast on Wednesday, March 13, 2024 at 4:30 p.m. ET to report its fourth quarter and full year financial results and provide an upd
CAMBRIDGE, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it has received clearance by the U.S. Food and Drug Administration (FDA) for its investigational new drug (IND) application, to evaluate SPR206 in a Phase 2 clinical study.
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel therapies for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Cowen 44th Annual Healthcare Conference, which is taking place
Sath Shukla, CEO and President of Spero Therapeutics Inc (NASDAQ:SPRO), sold 75,994 shares of the company on February 5, 2024, according to a recent SEC Filing.